UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 161 filers reported holding UNIQURE NV in Q3 2019. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $431,569 | +3.2% | 19,037 | -14.6% | 0.00% | – |
| Q3 2022 | $418,000 | +105.9% | 22,287 | +104.4% | 0.00% | – |
| Q2 2022 | $203,000 | -9.4% | 10,901 | -27.3% | 0.00% | – |
| Q1 2022 | $224,000 | -40.4% | 14,992 | +88.8% | 0.00% | – |
| Q1 2020 | $376,000 | -13.0% | 7,942 | +31.9% | 0.00% | -100.0% |
| Q4 2019 | $432,000 | +332.0% | 6,023 | +136.4% | 0.00% | – |
| Q3 2019 | $100,000 | -94.6% | 2,548 | -95.0% | 0.00% | -100.0% |
| Q3 2018 | $1,844,000 | -8.8% | 50,660 | -5.2% | 0.00% | 0.0% |
| Q2 2018 | $2,021,000 | +15.7% | 53,460 | -28.1% | 0.00% | 0.0% |
| Q1 2018 | $1,747,000 | +34.6% | 74,320 | +12.1% | 0.00% | +33.3% |
| Q4 2017 | $1,298,000 | +14322.2% | 66,270 | +5544.8% | 0.00% | – |
| Q2 2016 | $9,000 | -35.7% | 1,174 | +2.1% | 0.00% | – |
| Q1 2016 | $14,000 | -22.2% | 1,150 | +8.5% | 0.00% | – |
| Q4 2015 | $18,000 | -14.3% | 1,060 | +5.7% | 0.00% | – |
| Q3 2015 | $21,000 | +31.2% | 1,003 | +66.1% | 0.00% | – |
| Q2 2015 | $16,000 | – | 604 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |